Immunization, Hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, Hib3 was 83.7% in 2024. ◆ Volatile
Immunization, Hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), 1990–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
The most recent figure for immunization, hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) is 83.7%, measured in 2024.
The figure is up 0.1% on the previous year and up 19.2% over ten years.
Over the whole period, immunization, hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) peaked at 84.6% in 2019 and was at its lowest, 0.0%, in 1990.
That places Middle East, North Africa, Afghanistan & Pakistan (excluding high income) 20th out of 43 groups with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, Hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1990 | 0.0% | — |
| 1991 | 0.0% | — |
| 1992 | 0.0% | — |
| 1993 | 0.0% | — |
| 1994 | 0.0% | — |
| 1995 | 0.0% | — |
| 1996 | 0.0% | — |
| 1997 | 0.0% | — |
| 1998 | 0.0% | — |
| 1999 | 0.0% | — |
| 2000 | 0.0% | — |
| 2001 | 4.0% | — |
| 2002 | 4.4% | +9.3% |
| 2003 | 6.1% | +38.8% |
| 2004 | 6.0% | -1.2% |
| 2005 | 8.2% | +37.8% |
| 2006 | 9.1% | +11.0% |
| 2007 | 15.0% | +63.5% |
| 2008 | 20.5% | +37.0% |
| 2009 | 45.1% | +119.8% |
| 2010 | 45.3% | +0.6% |
| 2011 | 49.5% | +9.1% |
| 2012 | 52.0% | +5.1% |
| 2013 | 54.3% | +4.4% |
| 2014 | 70.2% | +29.3% |
| 2015 | 79.4% | +13.2% |
| 2016 | 81.2% | +2.2% |
| 2017 | 81.5% | +0.4% |
| 2018 | 83.4% | +2.3% |
| 2019 | 84.6% | +1.4% |
| 2020 | 80.8% | -4.5% |
| 2021 | 81.4% | +0.7% |
| 2022 | 83.5% | +2.6% |
| 2023 | 83.6% | +0.2% |
| 2024 | 83.7% | +0.1% |
Biggest year-on-year movements
Years where Immunization, Hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2009 | +119.8% | 20.5% | 45.1% |
| 2007 | +63.5% | 9.1% | 15.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | 10 |
| 2000s | 11.8% | 0.0% | 45.1% | 10 |
| 2010s | 68.1% | 45.3% | 84.6% | 10 |
| 2020s | 82.6% | 80.8% | 83.7% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
More health data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 3.11 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0305 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 3.21 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0351 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.51 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0341 units per person (2025)
- Population ages 30-34, female, annual growth rate 0.4849 % change on previous year (2025)
All data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) →
Frequently asked questions
- What is immunization, hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Immunization, hib3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) was 83.7% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The highest recorded value was 84.6% in 2019.
- What is the lowest immunization, hib3 recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The lowest recorded value was 0.0% in 1990.
- How does Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank for immunization, hib3?
- Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 20th out of 43 groups with data for 2024.
- Is immunization, hib3 rising or falling in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Over the last ten years it is up 19.2%. The long-run trend across the full record is volatile.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (excluding high income) data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 35 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.